These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37951155)

  • 1. Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.
    Kim SQ; Kim J; Choi M; Kim Y; Kim S; Kim KH
    Biochem Biophys Res Commun; 2023 Dec; 688():149164. PubMed ID: 37951155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of acyl-coenzyme A:cholesterol acyltransferase alleviates obesity and insulin resistance in diet-induced obese mice by regulating food intake.
    Zhu Y; Kim SQ; Zhang Y; Liu Q; Kim KH
    Metabolism; 2021 Oct; 123():154861. PubMed ID: 34371065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
    Thorsø Larsen A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
    Amaro A; Sugimoto D; Wharton S
    Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
    Lau DCW; Batterham RL; le Roux CW
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
    Singh G; Krauthamer M; Bjalme-Evans M
    J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin.
    Melander SA; Katri A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Jan; 938():175397. PubMed ID: 36414113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.
    Martins FF; Marinho TS; Cardoso LEM; Barbosa-da-Silva S; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
    Cell Biochem Funct; 2022 Dec; 40(8):903-913. PubMed ID: 36169111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide for Weight Loss: Was It Worth the Weight?
    Novograd J; Mullally J; Frishman WH
    Cardiol Rev; 2022 Nov-Dec 01; 30(6):324-329. PubMed ID: 36201244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
    Reis-Barbosa PH; Marcondes-de-Castro I; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    Diabetes Obes Metab; 2024 Oct; 26(10):4613-4621. PubMed ID: 39113264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice.
    Liu D; Gu J; Shao W; Pang J; Qian X; Jin T
    Can J Diabetes; 2022 Apr; 46(3):216-224.e2. PubMed ID: 35568421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.